Manulife (Manufacturers Life Insurance)
AVTX icon

Manulife (Manufacturers Life Insurance)’s Avalo Therapeutics AVTX Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6
Closed -$42K – 2844
2020
Q1 		$42K Buy
+6
New +$63.5K ﹤0.01% 2752

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s AVTX Position: Q2 2020 in Review

Manulife (Manufacturers Life Insurance) sold out of Avalo Therapeutics (AVTX) in Q2 2020, closing a stake of 6 shares — an estimated $42K sold.

Manulife (Manufacturers Life Insurance) first reported a position in AVTX in Q1 2020 and held it in 1 quarter. The position peaked at $42K in Q1 2020. 55 funds tracked by Wall St. Rank hold AVTX as of Q2 2020.

  • Manulife (Manufacturers Life Insurance) reported no remaining Avalo Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 6 Avalo Therapeutics shares in Q2 2020, an estimated $42K.
  • Manulife (Manufacturers Life Insurance) first reported a position in Avalo Therapeutics in Q1 2020 and held it in 1 quarter.
  • Manulife (Manufacturers Life Insurance)'s Avalo Therapeutics position peaked at $42K in Q1 2020.
  • 55 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2020.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2020, filed 10 Aug 2020.